Our Recommendations
- Ulcère de Buruli : prise en charge de l' infection à Mycobacterium ulcerans (2001)
- Traitement de l’infection à mycobacterium ulcerans (ulcère de Buruli) (2012)
- Ulcère de buruli : diagnostic de l' infection à mycobacterium ulcerans (2001)
- Recognizing neglected tropical diseases through changes on the skin: a training guide for front-line health workers (2018)
- Laboratory diagnosis of Buruli ulcer (2014)
New Publications
- Buruli Ulcer Disease: Mycobacterium Ulcerans Infection (2009)
- Report of the fifth annual meeting of the network of Buruli ulcer PCR laboratories in the WHO African Region, Accra, Ghana, 23-25 October 2023 (2024)
- Rapid Extraction Method of Mycobacterium ulcerans DNA from Clinical Samples of Suspected Buruli Ulcer Patients (2019)
- A combined effort of 11 laboratories in the WHO African region to improve quality of Buruli ulcer PCR diagnosis: The “BU-LABNET” (2024)
- Buruli ulcer disease: rethinking diagnostic technique (2024)
Filter
95
Featured
Recommendations
14
New Publications
3
Language
Document type
Studies & Reports
34
Guidelines
15
Manuals
10
Videos
8
Resource Platforms
7
Brochures
6
Fact sheets
5
Infographics
4
No document type
3
Training Material
2
App
1
Countries / Regions
Global
7
Ghana
1
Nigeria
1
Authors & Publishers
Publication Years
Category
Clinical Guidelines
16
Pharmacy & Technologies
4
Countries
2
Public Health
1
Key Resources
1
Website - last accessed on 18.03.2023
In the 126 years since it was first described, scientists have learned a great deal about Buruli ulcer, (an ulcerating skin infection caused by the environmental bacterium, Mycobacterium ulcerans), including how to treat it. Yet, there is 1 question about this neglected tropical disease that has rem...
Buruli ulcer (BU), a neglected tropical disease (NTD), is an infection of the skin and subcutaneous tissue caused by Mycobacterium ulcerans. The disease has been documented in many South American, Asian, and Western Pacific countries and is widespread throughout much of Africa, especially in West...
Status of endemicity of Buruli ulcer 2023
Datos y cifras
La úlcera de Buruli es una enfermedad crónica y debilitante causada por una micobacteria ambiental: Mycobacterium ulcerans.
Al menos 33 países de clima tropical, subtropical o templado han notificado casos de úlcera de Buruli en África, América del Sur y las regiones...
In 2009, WHO’s Second International Conference on Buruli Ulcer Control and Research resolved to strengthen the capacity of national laboratories to confirm cases of the disease, but advised that “efforts are still needed to develop simple diagnostic tools usable in the field as well as disabilit...
Principaux faits
L’ulcère de Buruli est une infection chronique débilitante causée par la bactérie Mycobacterium ulcerans.
L’ulcère de Buruli a été signalé dans au moins 33 pays situés dans des régions au climat tropical, subtropical ou tempéré d’Afrique, d’Amérique ...
Key facts
Buruli ulcer is a chronic debilitating disease caused by an environmental Mycobacterium ulcerans.
At least 33 countries with tropical, subtropical and temperate climates have reported Buruli ulcer in Africa, South America and Western Pacific regions.
It often affects the skin an...
The Lancet Volume 399, Issue 10327p786-797February 26, 2022
Free download after free registration
Journal of Computational Biophysics and ChemistryVol. 22, No. 01, pp. 31-41 (2023)
Countries where buruli ulcer is endemic
August 26, 2021
https://doi.org/10.1371/journal.pntd.0009678
This manual details a collaboratively developed intervention to detect and refer Buruli ulcer, Hydrocele, Leprosy
and Lymphedema cases through the use of integrated approaches at community levels. This intervention has
been developed as part of the consortium in partnership with the Nigerian Feder...
Buruli ulcer (BU), the second most common mycobacterial disease in West Africa, is a necrotizing skin disease that can lead to high morbidity in affected patients. The disease is caused by Mycobacterium ulcerans (MU), whose major virulence factor is mycolactone. Although early infection can be treat...
L’ulcère de Buruli, une infection causée par Mycobacterium ulcerans, touche plus de 33 pays dans le monde, mais un peu moins de la moitié seulement de ces pays communiquent régulièrement des données sur la maladie à l’OMS.
Phillips and colleagues have shown that rifampicin combined with clarithromycin is non-inferior to RS8, and is safer. This much anticipated trial provides us with a high degree of confidence that an 8-week course of oral rifampicin and clarithromycin should now be the cornerstone of the treatment of...
The Lancet olume 395, ISSUE 10232, P1259-1267, April 18, 2020. Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral rifa...
Au total, 18 laboratoires de 13 pays ont participé aux quatre cycles d'AQE : 10 laboratoires de huit pays africains endémiques, dont quatre ont participé aux quatre cycles et trois à trois cycles. Les résultats globaux ont montré que la performance médiane de ces laboratoires s'est amélioré...
Research to develop point-of-care tests is in progress. Treatment of Buruli ulcer comprises 8 weeks of combined antibiotics (rifampicin and clarithromycin). Complementary therapies such as wound care, skin graft and prevention of disability are needed in some cases to ensure full recovery.
The targ...
A total of 18 laboratories from 13 countries participated in the four rounds of EQA: 10 laboratories from eight African endemic countries, four of which participated in all four rounds and three in three rounds. The overall results showed that the median performance of these laboratories improved ov...
